Bluejay Diagnostics, Inc.
BJDX$3M
Micro CapNASDAQSurgical & Medical Instruments & Apparatus🇺🇸North AmericaACTON
Drugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 15, 2026
22wMarket Overview
Stock performance and key metrics
BJDX News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
Brelovitug 900 mg
Chronic Hepatitis D Infection
Brelovitug 300 mg
Chronic Hepatitis D Infection
Bulevirtide 2 mg and Brelovitug - 300 mg
Chronic Hepatitis D Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brelovitug 900 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Brelovitug 300 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Bulevirtide 2 mg and Brelovitug - 300 mg | Phase 3 | Chronic Hepatitis D Infection | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply